EVMN
insider transactionsEvommune, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-71.9K
0 buy · 71.9K sell
Net value · 365d
-$1.6M
$0 in · $1.6M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
6
0 buy · 71.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
15.7K sh
Own New
-
Grant·A
Director
$0
15.7K sh
Own New
-
Grant·A
Director · 10b5-1
$0
15.7K sh
Own New
-
Sell·S
Director · 10b5-1
$12.8K
600 sh · $21.38
Own -3%
-
Sell·S
Director · 10b5-1
$110.3K
5.5K sh · $20.21
Own -23%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
13.5K sh
Own +85%
-
Sell·S
Chief Scientific Officer · 10b5-1
$379.5K
16.7K sh · $22.74
Own -26%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$51.9K
13.5K sh · $3.84
Own +27%
-
Sell·S
Luis C. Pena KEY
President & CEO · 10b5-1
$381.7K
16.8K sh · $22.74
Own -3%
-
Exercise·M
Chief Business & Legal Officer · 10b5-1
$0
14.2K sh
Own +42%
-
Sell·S
Chief Business & Legal Officer · 10b5-1
$324.7K
14.2K sh · $22.83
Own -19%
-
Exercise·M
Chief Business & Legal Officer · 10b5-1
$24.3K
14.2K sh · $1.71
Own +23%
-
Exercise·M
Kyle Carver KEY
Chief Financial Officer · 10b5-1
$0
15.0K sh
Own +18%
-
Sell·S
Kyle Carver KEY
Chief Financial Officer · 10b5-1
$415.1K
18.2K sh · $22.84
Own -23%
-
Exercise·M
Kyle Carver KEY
Chief Financial Officer · 10b5-1
$44.9K
15.0K sh · $2.99
Own +24%
-
Grant·A
Chief Scientific Officer
$0
69.3K sh
Own New
-
Grant·A
Chief Business & Legal Officer
$0
115.3K sh
Own New
-
Grant·A
Luis C. Pena KEY
President & CEO
$0
291.4K sh
Own New
-
Grant·A
Chief of Dev. Operations
$0
73.9K sh
Own New
-
Grant·A
Kyle Carver KEY
Chief Financial Officer
$0
98.9K sh
Own New
-
Grant·A
Chief Medical Officer
$0
51.1K sh
Own New
-
Grant·A
$1000.0K
35.9K sh · $27.88
Own +1%
-
Grant·A
Weegen Felice Isabel Verduyn-Van
Director, 10% Owner
$10.0M
358.7K sh · $27.88
Own +7%
-
Grant·A
Director, 10% Owner
$10.0M
358.7K sh · $27.88
Own +7%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | Arthur S Kirsch | Grant A | 15.7K | $0 |
| Jun 2, 2026 | Benjamin F Mcgraw III | Grant A | 15.7K | $0 |
| Jun 2, 2026 | David E Cohen 10b5-1 | Grant A | 15.7K | $0 |
| Jun 2, 2026 | David E Cohen 10b5-1 | Sell S | 600 | $12.8K |
| Jun 2, 2026 | David E Cohen 10b5-1 | Sell S | 5.5K | $110.3K |
| Jun 1, 2026 | Jeegar Pravinkumar Patel 10b5-1 | Exercise M | 13.5K | $0 |
| Jun 1, 2026 | Jeegar Pravinkumar Patel 10b5-1 | Sell S | 16.7K | $379.5K |
| Jun 1, 2026 | Jeegar Pravinkumar Patel 10b5-1 | Exercise M | 13.5K | $51.9K |
| Jun 1, 2026 | Luis C. Pena KEY 10b5-1 | Sell S | 16.8K | $381.7K |
| May 28, 2026 | Gregory S. Moss 10b5-1 | Exercise M | 14.2K | $0 |
| May 28, 2026 | Gregory S. Moss 10b5-1 | Sell S | 14.2K | $324.7K |
| May 28, 2026 | Gregory S. Moss 10b5-1 | Exercise M | 14.2K | $24.3K |
| May 28, 2026 | Kyle Carver KEY 10b5-1 | Exercise M | 15.0K | $0 |
| May 28, 2026 | Kyle Carver KEY 10b5-1 | Sell S | 18.2K | $415.1K |
| May 28, 2026 | Kyle Carver KEY 10b5-1 | Exercise M | 15.0K | $44.9K |
| Apr 16, 2026 | Jeegar Pravinkumar Patel | Grant A | 69.3K | $0 |
| Apr 16, 2026 | Gregory S. Moss | Grant A | 115.3K | $0 |
| Apr 16, 2026 | Luis C. Pena KEY | Grant A | 291.4K | $0 |
| Apr 16, 2026 | Janice Suzann Drew | Grant A | 73.9K | $0 |
| Apr 16, 2026 | Kyle Carver KEY | Grant A | 98.9K | $0 |
| Apr 16, 2026 | Eugene Bauer | Grant A | 51.1K | $0 |
| Feb 17, 2026 | RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah | Grant A | 35.9K | $1000.0K |
| Feb 17, 2026 | Weegen Felice Isabel Verduyn-Van | Grant A | 358.7K | $10.0M |
| Feb 17, 2026 | LSP 7 Cooperative UA | Grant A | 358.7K | $10.0M |
About EVMN insider trading
This page tracks insider transactions for Evommune, Inc. (EVMN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.